Oxford Medical Diagnostics adds Prof Graham Richards to Science
7 Feb 2011
Oxford Medical Diagnostics, a developer of advanced diagnostic
technology has announced that Professor Graham Richards is joining the
company’s Science Advisory Panel.
Professor Richards, head of the Centre for Computational Drug
Discovery at Oxford University, brings his considerable expertise in
life sciences. He has also contributed to the success of a number of
technology-based start-up companies and will be able to advise the
company on its development strategy.
“Graham Richards boosts the scientific excellence in the Oxford
Medical Diagnostics team and will provide valuable input on our
development strategy,” said Oxford Medical Diagnostics CEO, Tony
Marchington. “Our Science Advisory Panel includes leading
international scientists and a wide range of experience in the
science and technology field.”
Professor Richards was a co-founder of one of Oxford University’s
most successful spin-offs, along with Marchington. The company,
Oxford Molecular Group plc, reached a FTSE 250 valuation of £475
million. Professor Richards is one of the leading computational
chemists in the UK, with over 300 publications. He served as
Chairman of the Department of Chemistry at Oxford University from
1997 to 2007. He is head of the Centre for Computational Drug
Discovery at Oxford.
Throughout his career, Professor Richards has been involved in
the commercialization of technologies. In 2001, he founded InhibOx
Ltd. He was a director of ISIS Innovation Ltd, the University of
Oxford's technology transfer company and was involved for several
years with the Wellcome Trust in a similar capacity. He is also a
main board director (formerly chairman) of IP Group plc, the listed
intellectual property commercialization company.
Oxford Medical Diagnostics Ltd is developing technology that
makes it possible to provide rapid, accurate and low-cost diagnosis
and monitoring of disease and metabolic functions. Its initial
objective is to bring to market a non-invasive point-of-care
diagnostic instrument to detect diabetes types 1 and 2 by detection
of acetone in the breath.